Celebrating the EMP16 success story through strategic PR

Empros Pharma

The situation

Sweden-based biotech, Empros Pharma is on a mission to bring their weight management treatment to market within the next three years. They approached us for our support to announce a successful outcome of the Phase 2 trial of its weight loss & management therapy, EMP16.

Ten years in the making, this is a pivotal moment for the company, which needs significant investment to begin Phase 3 trials and launch the product to market by 2027.

The need

To ramp up its search for investment, Empros was keen for the trial’s success to be noticed. 

There is a lot of competition for weight loss products right now, and Empros was open to investment from either a big pharma company looking for a weight loss/management therapy or a biotech investor interested in this market. 

It was clear that CEO, Arvid Söderhall had an engaging story to tell, so we worked to center the press coverage around their ten-year journey and the EMP16 success story.

What we did

The drug’s unique differentiators, such as its oral aspect and focus on long-term weight management, were a key element of the press release and the exclusive interview we secured with EndPoints News.

The interview with the Empros CEO was well-received, and a LinkedIn post was prepared to announce the interview to their network.

Targeting was then widened to other media outlets such as national media, clinical trials press and a selection of other pharma titles to maximize media coverage.

The impact

Check out the full press release.

Our strategic media relations campaign resulted in a coveted exclusive interview with EndPoints News, a highly respected biopharma publication read by industry professionals including R&D professionals, clinicians and investors. The publication has 700k readership and a strong domain authority. The LinkedIn Post also helped to boost engagement and update Empros’ network on the successful trial.

The client was thrilled with the impact of the media attention, which garnered significant interest in EMP16. The positive press coverage has sparked promising conversations for Empros Pharma, propelling EMP16 into the next phase of its market journey with great momentum.